22 Einstein Street
Floor 4
Ness Ziona 7414003
Israel
972 7 2394 2377
https://www.biomx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 58
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Jonathan Eitan Solomon MBA | CEO & Director | 714,37k | N/A | 1977 |
Dr. Merav Bassan Ph.D. | Chief Development Officer | 437,71k | N/A | 1966 |
Ms. Marina Wolfson CPA | CFO & Secretary (Leave of Absence) | 337,51k | N/A | 1984 |
Prof. Rotem Sorek Ph.D. | Scientific Founder | N/A | N/A | N/A |
Dr. Eran Elinav M.D., Ph.D. | Scientific Founder | N/A | N/A | N/A |
Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder | N/A | N/A | 1981 |
Mr. Avraham Gabay | Interim Chief Financial Officer | N/A | N/A | 1986 |
Ms. Inbal Benjamini-Elran | C.H.R.O | N/A | N/A | N/A |
Mr. Assaf Oron | Chief Business Officer | 352,04k | N/A | 1974 |
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
El ISS Governance QualityScore de BiomX Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.